Acutaas Chemicals Limited Fundamental Analysis (BSE: ACUTAAS.BO)
Acutaas Chemicals Limited Fundamental Analysis (BSE: ACUTAAS.BO)
Acutaas Chemicals Limited (BSE: ACUTAAS.BO) shows moderate financial fundamentals with a PE ratio of 246.57, profit margin of 20.70%, and ROE of 8.12%. The company generates $5.2B in annual revenue with strong year-over-year growth of 40.34%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ACUTAAS.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakACUTAAS.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateACUTAAS.BO shows balanced valuation metrics.
Growth Score
ExcellentACUTAAS.BO delivers strong and consistent growth momentum.
Financial Health Score
ModerateACUTAAS.BO shows balanced financial health with some risks.
Profitability Score
WeakACUTAAS.BO struggles to sustain strong margins.
Key Financial Metrics
Is ACUTAAS.BO Expensive or Cheap?
P/E Ratio
ACUTAAS.BO trades at 246.57 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ACUTAAS.BO's PEG of 1.10 indicates fair valuation.
Price to Book
The market values Acutaas Chemicals Limited at 20.20 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 199.64 times EBITDA. This signals the market has high growth expectations.
How Well Does ACUTAAS.BO Make Money?
Net Profit Margin
For every $100 in sales, Acutaas Chemicals Limited keeps $20.70 as profit after all expenses.
Operating Margin
Core operations generate 35.71 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.12 in profit for every $100 of shareholder equity.
ROA
Acutaas Chemicals Limited generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Acutaas Chemicals Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Acutaas Chemicals Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
ACUTAAS.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
246.57
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.10
vs 25 benchmark
P/B Ratio
Price to book value ratio
20.20
vs 25 benchmark
P/S Ratio
Price to sales ratio
51.71
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How ACUTAAS.BO Stacks Against Its Sector Peers
| Metric | ACUTAAS.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 246.57 | 27.38 | Worse (Expensive) |
| ROE | 8.12% | 967.00% | Weak |
| Net Margin | 20.70% | -1512.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.64 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 3.17 | Weak Liquidity |
| ROA | 0.00% | 554.00% | Weak |
ACUTAAS.BO outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Acutaas Chemicals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
65.19%
Industry Style: Cyclical, Commodity, Value
High GrowthEPS CAGR
127.16%
Industry Style: Cyclical, Commodity, Value
High GrowthFCF CAGR
71.84%
Industry Style: Cyclical, Commodity, Value
High Growth